Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587611 | 0.97 | ALDH1A1 (0.60) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL337085 | 0.94 | ALDH1A1 (0.70) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL10602483 | 0.92 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL3421776 | 0.92 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL98282 | 0.92 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL2871721 | 0.92 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL4137591 | 0.89 | ALDH1A1 (0.71) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL929568 | 0.89 | ALDH1A1 (0.71) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL10299523 | 0.88 | CYP1A2 (0.52) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL9681942 | 0.88 | ALDH1A1 (0.54) | ALDH1A1CYP1A2USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3109239-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-28 | — | — | EP | disclosed |
| CN-105980363-A | Aminopyrazolone Derivatives | 第三共株式会社 | 2016-09-28 | — | — | CN | disclosed |
| US-9284283-B2 | Macrocyclic compounds for modulating IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284283-B2 | Macrocyclic compounds for modulating IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2809660-B1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2809660-B1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| WO-2013116682-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-1200406-B1 | CYCLIC AMIDES AND IMIDES HAVING SELECTIVE ANTAGONIST ACTIVITY AT ALPHA-1D ADRENERGIC RECEPTOR | RECORDATI CHEM PHARM (IT) | 2004-11-24 | — | — | EP | disclosed |
| EP-0854131-B1 | PROCESS FOR THE PREPARATION OF ALKYL CARBOXYLATES | TORAY INDUSTRIES (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-1200406-A1 | CYCLIC AMIDES AND IMIDES HAVING SELECTIVE ANTAGONIST ACTIVITY AT ALPHA-1D ADRENERGIC RECEPTOR | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001005765-A1 | CYCLIC AMIDES AND IMIDES HAVING SELECTIVE ANTAGONIST ACTIVITY AT ALPHA-1D ADRENERGIC RECEPTOR | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2001-01-25 | — | — | WO | disclosed |
| US-6087527-A | Method for producing alkyl carboxylates by multi-stage esteridication interrupted with a dehydration step | TORAY INDUSTRIES, INC. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0854131-A1 | PROCESS FOR THE PREPARATION OF ALKYL CARBOXYLATES | TORAY INDUSTRIES, INC. (JP) | 1998-07-22 | — | — | EP | disclosed |
| US-4098830-A | OXIDATIVE COUPLING OF ALKYLPHENOLS OR 1-NAPHTHOLS CATALYZED BY METAL COMPLEXES OF DICARBOXYLIC ACID COMPOUNDS | ICI AMERICAS INC. (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | ALDH1A1 815/4885CYP1A2 111/4885USP2 4290/4885 |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | ATAD5, ATP1A1, TIPRL | ALDH1A1 2821/4885CYP1A2 2334/4885USP2 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.